Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.53 |
| ▸ | FLT1 | P17948 | 4/20 | 0.53 |
| ▸ | FLT4 | P35916 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 7/20 | 0.46 |
| ▸ | MET | P08581 | 7/20 | 0.46 |
| ▸ | TEK | Q02763 | 7/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580589 | 0.90 | KDR (0.52) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL278841 | 0.86 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2466794 | 0.85 | KDR (0.60) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2471122 | 0.82 | KDR (0.62) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468937 | 0.82 | KDR (0.66) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2467944 | 0.82 | KDR (0.71) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468872 | 0.81 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL272701 | 0.81 | KDR (0.50) | KDRFLT1RETPDE4BAURKA | |
| SCHEMBL2469664 | 0.80 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2468856 | 0.79 | KDR (0.75) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | KDR 3083/4885FLT1 2466/4885FLT4 3490/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | KDR 1319/4885FLT1 1353/4885FLT4 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.